Literature DB >> 16838170

Single nucleotide polymorphisms of the HNF4alpha gene are associated with the conversion to type 2 diabetes mellitus: the STOP-NIDDM trial.

Laura Andrulionyte1, Olli Laukkanen, Jean-Louis Chiasson, Markku Laakso.   

Abstract

Hepatocyte nuclear factor 4alpha (HNF4alpha) is a transcription factor, which is necessary for normal function of human liver and pancreatic islets. We investigated whether single nucleotide polymorphisms (SNPs) of HNF4A, encoding HNF4alpha, influenced the conversion from impaired glucose tolerance (IGT) to type 2 diabetes mellitus in subjects of the STOP-NIDDM trial. This trial aimed at evaluating the effect of acarbose compared to placebo in the prevention of type 2 diabetes mellitus. Eight SNPs covering the intragenic and alternate P2 promoter regions of HNF4A were genotyped in study samples using the TaqMan Allelic Discrimination Assays. Three SNPs in the P2 promoter region (rs4810424, rs1884614, and rs2144908) were in almost complete association (D'>0.97, r (2)>0.95) and, therefore, only rs4810424 was included in further analyses. Female carriers of the less frequent C allele of rs4810424 had a 1.7-fold elevated risk [95% confidence interval (CI) 1.09-2.66; P=0.020] for the conversion to diabetes compared to women with the common genotype after the adjustment for age, treatment group (placebo or acarbose), smoking, weight at baseline, and weight change. No association was found in men. Haplotype analysis based on three SNPs (rs4810424, rs2071197, and rs3818247) representing the linkage disequilibrium blocks in our study population indicated that the conversion to type 2 diabetes mellitus was dependent on the number of risk alleles in different haplotypes in women. Our results suggest that SNPs of HNF4A and their haplotypes predispose to type 2 diabetes mellitus in female subjects of the STOP-NIDDM study population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16838170     DOI: 10.1007/s00109-006-0063-3

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  28 in total

Review 1.  Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young.

Authors:  S S Fajans; G I Bell; K S Polonsky
Journal:  N Engl J Med       Date:  2001-09-27       Impact factor: 91.245

2.  Mutation in the HNF-4alpha gene affects insulin secretion and triglyceride metabolism.

Authors:  M Lehto; P O Bitzén; B Isomaa; C Wipemo; Y Wessman; C Forsblom; T Tuomi; M R Taskinen; L Groop
Journal:  Diabetes       Date:  1999-02       Impact factor: 9.461

3.  The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism.

Authors:  M Stoffel; S A Duncan
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

4.  A distant upstream promoter of the HNF-4alpha gene connects the transcription factors involved in maturity-onset diabetes of the young.

Authors:  H Thomas; K Jaschkowitz; M Bulman; T M Frayling; S M Mitchell; S Roosen; A Lingott-Frieg; C J Tack; S Ellard; G U Ryffel; A T Hattersley
Journal:  Hum Mol Genet       Date:  2001-09-15       Impact factor: 6.150

5.  Variation near the hepatocyte nuclear factor (HNF)-4alpha gene associates with type 2 diabetes in the Danish population.

Authors:  S K Hansen; C S Rose; C Glümer; T Drivsholm; K Borch-Johnsen; T Jørgensen; O Pedersen; T Hansen
Journal:  Diabetologia       Date:  2005-02-25       Impact factor: 10.122

6.  The common polymorphisms (single nucleotide polymorphism [SNP] +45 and SNP +276) of the adiponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.

Authors:  Jelena Zacharova; Jean-Louis Chiasson; Markku Laakso
Journal:  Diabetes       Date:  2005-03       Impact factor: 9.461

7.  Activation of the insulin gene promoter through a direct effect of hepatocyte nuclear factor 4 alpha.

Authors:  Reut Bartoov-Shifman; Rachel Hertz; Haiyan Wang; Claes B Wollheim; Jacob Bar-Tana; Michael D Walker
Journal:  J Biol Chem       Date:  2002-05-06       Impact factor: 5.157

8.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

9.  Hepatocyte nuclear factor 4alpha controls the development of a hepatic epithelium and liver morphogenesis.

Authors:  Fereshteh Parviz; Christine Matullo; Wendy D Garrison; Laura Savatski; John W Adamson; Gang Ning; Klaus H Kaestner; Jennifer M Rossi; Kenneth S Zaret; Stephen A Duncan
Journal:  Nat Genet       Date:  2003-07       Impact factor: 38.330

10.  Candidate gene association study in type 2 diabetes indicates a role for genes involved in beta-cell function as well as insulin action.

Authors:  Inês Barroso; Jian'an Luan; Rita P S Middelberg; Anne-Helen Harding; Paul W Franks; Rupert W Jakes; D Clayton; Alan J Schafer; Stephen O'Rahilly; Nicholas J Wareham
Journal:  PLoS Biol       Date:  2003-10-13       Impact factor: 8.029

View more
  3 in total

1.  Hepatocyte nuclear factor 4 alpha polymorphisms and the metabolic syndrome in French-Canadian youth.

Authors:  Valérie Marcil; Devendra Amre; Ernest G Seidman; François Boudreau; Fernand P Gendron; Daniel Ménard; Jean François Beaulieu; Daniel Sinnett; Marie Lambert; Emile Levy
Journal:  PLoS One       Date:  2015-02-11       Impact factor: 3.240

Review 2.  The pharmacogenetics of type 2 diabetes: a systematic review.

Authors:  Nisa M Maruthur; Matthew O Gribble; Wendy L Bennett; Shari Bolen; Lisa M Wilson; Poojitha Balakrishnan; Anita Sahu; Eric Bass; W H Linda Kao; Jeanne M Clark
Journal:  Diabetes Care       Date:  2014       Impact factor: 19.112

3.  Association between genetic variants in the HNF4A gene and childhood-onset Crohn's disease.

Authors:  V Marcil; D Sinnett; E Seidman; F Boudreau; F-P Gendron; J-F Beaulieu; D Menard; M Lambert; A Bitton; R Sanchez; D Amre; E Levy
Journal:  Genes Immun       Date:  2012-08-23       Impact factor: 2.676

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.